Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma

被引:0
作者
Gordon, Leo I. [1 ]
机构
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
来源
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2017年 / 15卷 / 5.5期
关键词
STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PD-1; BLOCKADE; TRIAL; NIVOLUMAB;
D O I
10.6004/jnccn.2017.0082
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The advent of effective therapies has improved outcomes for those with newly diagnosed Hodgkin lymphoma (HL), with a resulting cure rate of at least 80%. However, with limited data on therapeutic options in the setting of advanced disease, individualized treatment is recommended, and potential long-term effects of therapy remain a key consideration. At the NCCN 22nd Annual Conference, Dr. Leo I. Gordon explored strategies for systemic therapy in the relapsed or refractory setting, focusing primarily on the standard of high-dose therapy/autologous stem cell rescue, the CD30-targeted antibody drug conjugate brentuximab vedotin, and checkpoint inhibition.
引用
收藏
页码:716 / 718
页数:3
相关论文
共 7 条
[1]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[2]   Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC [J].
Herbaux, Charles ;
Gauthier, Jordan ;
Brice, Pauline ;
Fornecker, Luc ;
Bouabdallah, Krimo ;
Manson, Guillaume ;
Ghesquieres, Herve ;
Thiebaut-Bertrand, Anne ;
Demarquette, Helene ;
Boyle, Eileen ;
Ysebaert, Loic ;
Houot, Roch ;
Yakoub-Agha, Ibrahim ;
Morschhauser, Franck .
BLOOD, 2015, 126 (23)
[3]   Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma [J].
Merryman, Reid W. ;
Kim, Haesook T. ;
Zinzani, Pier Luigi ;
Carlo-Stella, Carmelo ;
Ansell, Stephen M. ;
Perales, Miguel-Angel ;
Avigdor, Abraham ;
Halwani, Ahmad S. ;
Houot, Roch ;
Marchand, Tony ;
Dhedin, Nathalie ;
Lescaut, Willy ;
Thiebaut-Bertrand, Anne ;
Francois, Sylvie ;
Stamatoullas-Bastard, Aspasia ;
Rohrlich, Pierre-Simon ;
Wallet, Helene Labussiere ;
Castagna, Luca ;
Santoro, Armando ;
Bachanova, Veronika ;
Bresler, Scott C. ;
Srivastava, Amitabh ;
Kim, Harim ;
Pesek, Emily ;
Chammas, Marie ;
Reynolds, Carol ;
Ho, Vincent T. ;
Antin, Joseph H. ;
Ritz, Jerome ;
Soiffer, Robert J. ;
Armand, Philippe .
BLOOD, 2017, 129 (10) :1380-1388
[4]   Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Moskowitz, Craig H. ;
Nademanee, Auayporn ;
Masszi, Tamas ;
Agura, Edward ;
Holowiecki, Jerzy ;
Abidi, Muneer H. ;
Chen, Andy I. ;
Stiff, Patrick ;
Gianni, Alessandro M. ;
Carella, Angelo ;
Osmanov, Dzhelil ;
Bachanova, Veronika ;
Sweetenham, John ;
Sureda, Anna ;
Huebner, Dirk ;
Sievers, Eric L. ;
Chi, Andy ;
Larsen, Emily K. ;
Hunder, Naomi N. ;
Walewski, Jan .
LANCET, 2015, 385 (9980) :1853-1862
[5]   Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial [J].
Schmitz, N ;
Pfistner, B ;
Sextro, M ;
Sieber, M ;
Carella, AM ;
Haenel, M ;
Boissevain, F ;
Zschaber, R ;
Müller, P ;
Kirchner, H ;
Lohri, A ;
Decker, S ;
Koch, B ;
Hasenclever, D ;
Goldstone, AH ;
Diehl, V .
LANCET, 2002, 359 (9323) :2065-2071
[6]   Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation [J].
Sureda, Anna ;
Canals, Carme ;
Arranz, Reyes ;
Caballero, Dolores ;
Ribera, Josep Maria ;
Brune, Mats ;
Passweg, Jacob ;
Martino, Rodrigo ;
Valcarcel, David ;
Besalduch, Joan ;
Duarte, Rafael ;
Leon, Angel ;
Jesus Pascual, Maria ;
Garcia-Noblejas, Ana ;
Lopez Corral, Lucia ;
Xicoy, Bianca ;
Sierra, Jordi ;
Schmitz, Norbert .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02) :310-317
[7]   Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial [J].
Younes, Anas ;
Santoro, Armando ;
Shipp, Margaret ;
Zinzani, Pier Luigi ;
Timmerman, John M. ;
Ansell, Stephen ;
Armand, Philippe ;
Fanale, Michelle ;
Ratanatharathorn, Voravit ;
Kuruvilla, John ;
Cohen, Jonathon B. ;
Collins, Graham ;
Savage, Kerry J. ;
Trneny, Marek ;
Kato, Kazunobu ;
Farsaci, Benedetto ;
Parker, Susan M. ;
Rodig, Scott ;
Roemer, Margaretha G. M. ;
Ligon, Azra H. ;
Engert, Andreas .
LANCET ONCOLOGY, 2016, 17 (09) :1283-1294